Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Cash (2016 - 2025)

Historic Change in Cash for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $6.7 million.

  • Zevra Therapeutics' Change in Cash fell 5448.27% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $400000.0, marking a year-over-year decrease of 9628.6%. This contributed to the annual value of -$9.3 million for FY2024, which is 5867.42% up from last year.
  • Latest data reveals that Zevra Therapeutics reported Change in Cash of $6.7 million as of Q3 2025, which was down 5448.27% from $10.4 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Change in Cash high stood at $71.7 million for Q1 2021, and its period low was -$25.3 million during Q1 2023.
  • Its 5-year average for Change in Cash is $2.6 million, with a median of -$792000.0 in 2021.
  • Per our database at Business Quant, Zevra Therapeutics' Change in Cash surged by 717838.1% in 2021 and then plummeted by 910636.36% in 2024.
  • Over the past 5 years, Zevra Therapeutics' Change in Cash (Quarter) stood at -$19.2 million in 2021, then surged by 76.02% to -$4.6 million in 2022, then surged by 95.21% to -$220000.0 in 2023, then crashed by 9106.36% to -$20.3 million in 2024, then skyrocketed by 133.21% to $6.7 million in 2025.
  • Its Change in Cash stands at $6.7 million for Q3 2025, versus $10.4 million for Q2 2025 and $3.6 million for Q1 2025.